Gustave RoussyVillejuif, Rhone-Alpes, France
Disclosure information not submitted.
Paper 44 - COMBINATION OF MDM2 AND CDK4/6 INHIIBITOR IN PATIENTS WITH ADVANCED WELL AND DE-DIFFERENCIATED LIPOSARCOMA AND OTHERS CANCERS: COHORT ANALYSIS FROM THE MEGAMOST PHASE II BASKET STUDY
Friday, November 15, 20249:00 AM – 10:00 AM PST
Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL
Saturday, November 16, 20243:30 PM – 4:30 PM PST
Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
